Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

Standards of Care II

Standards of Care II

Nurses bear specific legal responsibilities under several federal statutes, including:

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Treatment Resistent Cancers

Treatment Resistent Cancers

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Achieving Meaningful Use and Operational Efficiency.

Journal of oncology practice·2018

Same author

Benchmarking Practice Operations: Results From a Survey of Office-Based Oncology Practices.

Journal of oncology practice·2018

Same author

National Oncology Practice Benchmark, 2011 Report on 2010 Data.

Journal of oncology practice·2018

Same author

The National Practice Benchmark for Oncology, 2013 Report on 2012 Data.

Journal of oncology practice·2018

Same author

The Oncology Ecosystem: Oncology Practice Trends From the National Practice Benchmark.

Journal of oncology practice·2018

Same author

The National Practice Benchmark for Oncology: 2015 Report for 2014 Data.

Journal of oncology practice·2016

Search research articles

Related Experiment Video

Updated: Apr 20, 2026

Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model

Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model

Published on: April 18, 2025

The National Practice Benchmark for oncology, 2014 report on 2013 data.

Elaine L Towle¹, Thomas R Barr², James L Senese²

¹Oncology Metrics, a division of Flatiron Health, New York, NY etowle@oncomet.com.

Journal of Oncology Practice

|November 16, 2014

Summary

This summary is machine-generated.

The National Practice Benchmark (NPB) allows oncology practices to compare performance nationally. This report refines financial metrics and introduces clinical data density and radiation oncology benchmarks for better efficiency and care efficacy.

More Related Videos

Biobank for Translational Medicine: Standard Operating Procedures for Optimal Sample Management

Biobank for Translational Medicine: Standard Operating Procedures for Optimal Sample Management

Published on: November 30, 2022

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

Related Experiment Videos

Last Updated: Apr 20, 2026

Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model

Comparison of Predictive Performance of Three Lymph Node Staging Systems in Colorectal Signet Ring Cell Carcinoma Based on Machine Learning Model

Published on: April 18, 2025

Biobank for Translational Medicine: Standard Operating Procedures for Optimal Sample Management

Biobank for Translational Medicine: Standard Operating Procedures for Optimal Sample Management

Published on: November 30, 2022

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery

Published on: September 27, 2024

Area of Science:

Health Services Research
Oncology Management

Background:

Economic pressures necessitate efficiency and efficacy in oncology care.
The National Practice Benchmark (NPB) provides a tool for comparative performance analysis across diverse oncology practices.
Benchmarking is crucial for practices to navigate current economic challenges.

Purpose of the Study:

To present updated benchmarks for oncology practices.
To introduce new metrics for clinical data density and radiation oncology.
To refine financial reporting methodology for net medical revenue.

Main Methods:

Utilizing the National Practice Benchmark (NPB) survey data.
Reporting medical revenue net of drug costs as net medical revenue.
Introducing six new measures of clinical data density.
Expanding radiation oncology benchmarks.

Main Results:

Practices participating in the NPB demonstrate exceptional managerial capability.
Refined methodology captures gross margin attributable to drugs.
New clinical data density and radiation oncology benchmarks are introduced.

Conclusions:

The NPB facilitates meaningful comparisons between oncology practices of varying sizes and settings.
Continuous refinement of metrics enhances the ability of practices to monitor and benchmark performance.
The updated benchmarks support improved efficiency and efficacy of care in oncology settings.